Definium Therapeutics, Inc. Announces Proposed Public Offering
Definium Therapeutics announced a proposed underwritten public offering of $500 million in common shares and pre-funded warrants, with a 30-day option for underwriters to purchase up to $75 million additional shares. Net proceeds are intended to fund R&D of product candidates, prepare for the potential commercialization of DT120 ODT, and provide working capital.
Key figures
- Deal Value Usd
- 500000000
- Greenshoe option usd
- 75000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.